Business Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jul. 31, 2012		Jul. 31, 2011
Net revenue	$ 2,106		$ 1,634
Sales and marketing costs	709		688
Stock- based compensation expense	739		1,014
Personalized Oncology Solutions [Member]
Net revenue	918		601
Direct cost of services	(717)		(483)
Sales and marketing costs	(435)		(369)
Other operating expenses	0		0
Stock- based compensation expense	0	[1]	0	[1]
Segment profit (loss)	(234)		(251)
Translational Oncology Solutions [Member]
Net revenue	1,188		1,033
Direct cost of services	(691)		(419)
Sales and marketing costs	(192)		(245)
Other operating expenses	(363)		(517)
Stock- based compensation expense	0	[1]	0	[1]
Segment profit (loss)	(58)		(148)
Unallocated Corporate Overhead [Member]
Net revenue	0		0
Direct cost of services	0		0
Sales and marketing costs	0		0
Other operating expenses	(568)		(801)
Stock- based compensation expense	(739)	[1]	(1,014)	[1]
Segment profit (loss)	(1,307)		(1,815)
Consolidated [Member]
Net revenue	2,106		1,634
Direct cost of services	(1,408)		(902)
Sales and marketing costs	(627)		(614)
Other operating expenses	(931)		(1,318)
Stock- based compensation expense	(739)	[1]	(1,014)	[1]
Segment profit (loss)	$ (1,599)		$ (2,214)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.